[Highlight] Why Dog Longevity Drugs Are the Fastest Path to Human Longevity with Celine Halioua

What It Covers

Celine Halioua, founder of Loyal, explains why developing dog longevity drugs first is the fastest, most economically viable path to human longevity drugs, targeting five canine approvals by 2030.

Key Questions Answered

• •Dogs as translational models: Dog drug success rates are far more predictive for humans than mouse studies because dogs naturally develop dementia, cancer, and osteoarthritis like humans do. This could raise human drug trial success probability from 9% to roughly 40%, making billion-dollar human longevity studies financially viable.
• •Dog drug economics as a funding engine: Bringing a dog longevity drug from concept to approval costs approximately $50 million all-in, versus billions for human drugs. A small company can self-commercialize in the cash-pay pet market, generating revenue to fund subsequent human longevity research without big pharma dependency.
• •Human longevity trial design tension: Researchers face a catch-22 when designing human trials — intervening in older, high-risk individuals shortens study duration but reduces efficacy probability, while intervening earlier requires decades to see results. Choosing the right intervention window determines whether a company survives long enough to read out data.
• •Patent protection blocks human longevity drugs: Mechanisms well-established enough to clear safety bars for a human aging drug likely have insufficient remaining patent life to generate ROI post-approval. Identifying compounds with both strong biological evidence and viable patent protection is a core unsolved challenge for the field.